Sun Pharma Advanced Research Company Limited SPARC NSEPHARMA
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Healthy ROCE of 112.0%.
- Compounding revenue at 98.9% over 5 years.
- Profit CAGR of 265.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPARC Sun Pharma Advanced Research Company Limited NSEPHARMA | 212.11 | 4.43 | ₹6,883.43 Cr | - | 112.03% | - | 98.91% | 265.94% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 27.19 Cr | 9.64 Cr | 7.86 Cr | 8.45 Cr | 1,853.22 Cr |
| Cost of Revenue | - | 17.18 Cr | 10.67 Cr | 14.11 Cr | 13.48 Cr | 8.00 Cr |
| Gross Profit | - | 10.01 Cr | -1.03 Cr | -6.25 Cr | -5.03 Cr | 1,845.22 Cr |
| Operating Expenses | - | 66.14 Cr | 53.73 Cr | 62.03 Cr | 54.18 Cr | 74.42 Cr |
| Operating Income | - | -56.13 Cr | -54.76 Cr | -68.28 Cr | -59.21 Cr | 1,770.80 Cr |
| EBITDA | - | -53.18 Cr | -42.94 Cr | -65.71 Cr | -69.00 Cr | 1,775.00 Cr |
| Interest Expense | - | 4.54 Cr | 6.19 Cr | 7.52 Cr | 8.78 Cr | 11.64 Cr |
| Pretax Income | - | -60.67 Cr | -51.81 Cr | -75.79 Cr | -80.35 Cr | 1,760.96 Cr |
| Tax Provision | - | -90.00 L | 6.00 L | 6.00 L | 7.00 L | -38.00 L |
| Net Income | - | -59.77 Cr | -51.87 Cr | -75.85 Cr | -80.42 Cr | 1,761.34 Cr |
| Diluted EPS | - | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 238.78 Cr | 75.55 Cr | 71.77 Cr | 1,879.17 Cr |
| Cost of Revenue | - | 176.74 Cr | 135.79 Cr | 104.45 Cr | 46.26 Cr |
| Gross Profit | - | 62.04 Cr | -60.24 Cr | -32.68 Cr | 1,832.91 Cr |
| Operating Expenses | - | 285.69 Cr | 351.26 Cr | 302.85 Cr | 244.36 Cr |
| Operating Income | - | -223.64 Cr | -411.50 Cr | -335.53 Cr | 1,588.55 Cr |
| EBITDA | - | -203.18 Cr | -373.13 Cr | -321.35 Cr | 1,597.35 Cr |
| Interest Expense | - | 7.63 Cr | 1.19 Cr | 9.04 Cr | 34.13 Cr |
| Pretax Income | - | -222.58 Cr | -386.83 Cr | -342.78 Cr | 1,553.01 Cr |
| Tax Provision | - | 0 | 38.20 L | -27.00 L | -19.00 L |
| Net Income | - | -222.58 Cr | -387.21 Cr | -342.51 Cr | 1,553.20 Cr |
| Diluted EPS | - | -7.82 | -11.93 | -10.55 | 47.86 |
Compounded Sales Growth
| 5 Years: | 98.91% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 265.94% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +17.38% |
| 6 Months: | +59.69% |
| 3 Months: | +66.36% |
| 1 Month: | +48.29% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 830.13 Cr | 515.04 Cr | 335.53 Cr | 2,170.86 Cr |
| Current Assets | - | 454.96 Cr | 269.39 Cr | 26.20 Cr | 1,862.42 Cr |
| Cash & Equivalents | - | 58.36 L | 5.33 Cr | 1.96 Cr | 1.16 Cr |
| Inventory | - | - | - | - | - |
| Receivables | - | 32.71 Cr | 15.53 Cr | 16.06 Cr | 8.27 Cr |
| Total Liabilities | - | 317.35 Cr | 389.29 Cr | 552.48 Cr | 832.04 Cr |
| Current Liabilities | - | 178.95 Cr | 265.06 Cr | 374.24 Cr | 754.09 Cr |
| Long Term Debt | 0 | - | 0 | 100.00 Cr | 0 |
| Total Debt | - | 15.68 Cr | 57.66 Cr | 265.13 Cr | 559.31 Cr |
| Total Equity | - | 512.78 Cr | 125.76 Cr | -216.95 Cr | 1,338.82 Cr |
| Shares Outstanding | - | 32.45 Cr | 32.45 Cr | 32.45 Cr | 32.45 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -69.12 Cr | -429.19 Cr | -360.29 Cr | -238.77 Cr |
| Investing Cash Flow | - | -548.28 Cr | 391.53 Cr | 157.66 Cr | -23.50 Cr |
| Financing Cash Flow | - | 616.76 Cr | 42.41 Cr | 199.25 Cr | 261.39 Cr |
| Capital Expenditure | - | -15.39 Cr | -26.51 Cr | -10.34 Cr | -23.83 Cr |
| Free Cash Flow | - | -84.50 Cr | -455.70 Cr | -370.63 Cr | -262.60 Cr |
| Net Change in Cash | - | -64.06 L | 4.74 Cr | -3.38 Cr | -88.00 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 26.0% | -79.7% | -45.5% | 97.5% |
| Operating Margin % | - | -93.7% | -544.7% | -467.5% | 84.5% |
| Net Margin % | - | -93.2% | -512.6% | -477.2% | 82.7% |
| ROE % | - | -43.4% | -307.9% | 157.9% | 116.0% |
| ROCE % | - | -34.3% | -164.6% | 866.9% | 112.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPARC